Trials / Recruiting
RecruitingNCT06699602
A Study of Cemiplimab and Fianlimab in People With Clear Cell Renal Cell Carcinoma
A Pilot Phase II Study of Neoadjuvant Cemiplimab + Fianlimab in Patients With Locally Advanced Clear Cell Renal Cell Carcinoma Undergoing Nephrectomy
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 10 (estimated)
- Sponsor
- Memorial Sloan Kettering Cancer Center · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The researchers are doing this study to find out whether it is practical (feasible) to give cemiplimab and fianlimab before a nephrectomy and whether it causes any delays with surgery in people with kidney cancer. The researchers will also look at whether cemiplimab and fianlimab given before a nephrectomy is a safe and effective treatment approach and if there is a change in the size of the tumor following immunotherapy prior to planned surgery.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Cemiplimab | cemiplimab IV flat |
| DRUG | Fianlimab | fianilmab IV flat |
Timeline
- Start date
- 2025-02-11
- Primary completion
- 2028-02-01
- Completion
- 2028-02-01
- First posted
- 2024-11-21
- Last updated
- 2026-03-04
Locations
7 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06699602. Inclusion in this directory is not an endorsement.